Given that any immune therapy for a parasitic disease is likely to be combined with anti-parasitic drug treatment, we next examined the impact of combined anti-GITR and anti-IL-10R mAb treatment with a sub-optimal dose of the anti-parasitic drug sodium stibogluconate (Sbv). This evidence concerns the gene IL10RA and parasitic infectious disease.